Literature DB >> 21693703

Cannabinoid receptor type 1 (CB1R) signaling regulates hepatic gluconeogenesis via induction of endoplasmic reticulum-bound transcription factor cAMP-responsive element-binding protein H (CREBH) in primary hepatocytes.

Dipanjan Chanda1, Don-Kyu Kim, Tiangang Li, Yong-Hoon Kim, Seung-Hoi Koo, Chul-Ho Lee, John Y L Chiang, Hueng-Sik Choi.   

Abstract

Activated cannabinoid 1 receptor (CB1R) signaling has been implicated in the development of phenotypes associated with fatty liver, insulin resistance, and impaired suppression of hepatic glucose output. Endoplasmic reticulum stress-associated liver-specific transcription factor CREBH is emerging as a critical player in various hepatic metabolic pathways and regulates hepatic gluconeogenesis in diet-induced obese settings. In this study, we elucidated the critical role of CREBH in mediating CB1R signaling to regulate glucose homeostasis in primary rat and human hepatocytes. mRNA and protein levels and glucose production were analyzed in primary rat and human hepatocytes. ChIP assays were performed together with various transcriptional analyses using standard techniques. CB1R activation by 2-arachidonoylglycerol (2-AG) specifically induced CREBH gene expression via phosphorylation of the JNK signaling pathway and c-Jun binding to the AP-1 binding site in the CREBH gene promoter. 2-AG treatment significantly induced hepatic gluconeogenic gene expression and glucose production in primary hepatocytes, and we demonstrated that the CREBH binding site mutant significantly attenuated 2-AG-mediated activation of the gluconeogenic gene promoter. Endogenous knockdown of CREBH led to ablation of 2-AG-induced gluconeogenic gene expression and glucose production, and the CB1R antagonist AM251 or insulin exhibited repression of CREBH gene induction and subsequently inhibited gluconeogenesis in both rat and human primary hepatocytes. These results demonstrate a novel mechanism of action of activated CB1R signaling to induce hepatic gluconeogenesis via direct activation of CREBH, thereby contributing to a better understanding of the endocannabinoid signaling mechanism involved in regulating the hepatic glucose metabolism.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21693703      PMCID: PMC3151042          DOI: 10.1074/jbc.M111.224352

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  Endoplasmic reticulum stress increases glucose-6-phosphatase and glucose cycling in liver cells.

Authors:  Dong Wang; Yuren Wei; Dieter Schmoll; Kenneth N Maclean; Michael J Pagliassotti
Journal:  Endocrinology       Date:  2005-10-13       Impact factor: 4.736

2.  Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

Authors:  Jean-Pierre Després; Alain Golay; Lars Sjöström
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

3.  Activation of the peripheral endocannabinoid system in human obesity.

Authors:  Stefan Engeli; Jana Böhnke; Mareike Feldpausch; Kerstin Gorzelniak; Jürgen Janke; Sándor Bátkai; Pál Pacher; Judy Harvey-White; Friedrich C Luft; Arya M Sharma; Jens Jordan
Journal:  Diabetes       Date:  2005-10       Impact factor: 9.461

4.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Authors:  Luc F Van Gaal; Aila M Rissanen; André J Scheen; Olivier Ziegler; Stephan Rössner
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

5.  Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity.

Authors:  Douglas Osei-Hyiaman; Michael DePetrillo; Pál Pacher; Jie Liu; Svetlana Radaeva; Sándor Bátkai; Judith Harvey-White; Ken Mackie; László Offertáler; Lei Wang; George Kunos
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

6.  Regulation of hepatic gluconeogenesis by an ER-bound transcription factor, CREBH.

Authors:  Min-Woo Lee; Dipanjan Chanda; Jianqi Yang; Hyunhee Oh; Su Sung Kim; Young-Sil Yoon; Sungpyo Hong; Keun-Gyu Park; In-Kyu Lee; Cheol Soo Choi; Richard W Hanson; Hueng-Sik Choi; Seung-Hoi Koo
Journal:  Cell Metab       Date:  2010-04-07       Impact factor: 27.287

7.  Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress.

Authors:  K Haze; H Yoshida; H Yanagi; T Yura; K Mori
Journal:  Mol Biol Cell       Date:  1999-11       Impact factor: 4.138

Review 8.  Cannabinoids: potential anticancer agents.

Authors:  Manuel Guzmán
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

9.  Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response.

Authors:  Kezhong Zhang; Xiaohua Shen; Jun Wu; Kenjiro Sakaki; Thomas Saunders; D Thomas Rutkowski; Sung Hoon Back; Randal J Kaufman
Journal:  Cell       Date:  2006-02-10       Impact factor: 41.582

10.  Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice.

Authors:  Christine Ravinet Trillou; Michele Arnone; Claire Delgorge; Nadine Gonalons; Peter Keane; Jean-Pierre Maffrand; Philippe Soubrie
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2002-10-24       Impact factor: 3.619

View more
  27 in total

Review 1.  The role of CREB-H transcription factor in triglyceride metabolism.

Authors:  Ann-Hwee Lee
Journal:  Curr Opin Lipidol       Date:  2012-04       Impact factor: 4.776

2.  Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice.

Authors:  Jie Liu; Liang Zhou; Keming Xiong; Grzegorz Godlewski; Bani Mukhopadhyay; Joseph Tam; Shi Yin; Peter Gao; Xin Shan; James Pickel; Ramon Bataller; James O'Hare; Thomas Scherer; Christoph Buettner; George Kunos
Journal:  Gastroenterology       Date:  2012-01-31       Impact factor: 22.682

Review 3.  CB1 and CB2 Receptor Pharmacology.

Authors:  Allyn C Howlett; Mary E Abood
Journal:  Adv Pharmacol       Date:  2017-06-12

Review 4.  The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus.

Authors:  Alain Veilleux; Vincenzo Di Marzo; Cristoforo Silvestri
Journal:  Curr Diab Rep       Date:  2019-11-04       Impact factor: 4.810

5.  2-Arachidonoylglycerol ameliorates inflammatory stress-induced insulin resistance in cardiomyocytes.

Authors:  Dipanjan Chanda; Yvonne Oligschlaeger; Ilvy Geraets; Yilin Liu; Xiaoqing Zhu; Jieyi Li; Miranda Nabben; Will Coumans; Joost J F P Luiken; Jan F C Glatz; Dietbert Neumann
Journal:  J Biol Chem       Date:  2017-03-20       Impact factor: 5.157

Review 6.  The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake.

Authors:  Martin E Cooper; Simon E Regnell
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

7.  Activation of cannabinoid receptor type 1 (Cb1r) disrupts hepatic insulin receptor signaling via cyclic AMP-response element-binding protein H (Crebh)-mediated induction of Lipin1 gene.

Authors:  Dipanjan Chanda; Yong-Hoon Kim; Don-Kyu Kim; Min-Woo Lee; Su-Yeon Lee; Tae-Sik Park; Seung-Hoi Koo; Chul-Ho Lee; Hueng-Sik Choi
Journal:  J Biol Chem       Date:  2012-09-18       Impact factor: 5.157

8.  Pathophysiology of NASH: perspectives for a targeted treatment.

Authors:  Fabio Marra; Sophie Lotersztajn
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 9.  Endocannabinoid regulation of β-cell functions: implications for glycaemic control and diabetes.

Authors:  T Jourdan; G Godlewski; G Kunos
Journal:  Diabetes Obes Metab       Date:  2016-03-31       Impact factor: 6.577

10.  A novel control of human keratin expression: cannabinoid receptor 1-mediated signaling down-regulates the expression of keratins K6 and K16 in human keratinocytes in vitro and in situ.

Authors:  Yuval Ramot; Koji Sugawara; Nóra Zákány; Balázs I Tóth; Tamás Bíró; Ralf Paus
Journal:  PeerJ       Date:  2013-02-19       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.